P-cadherin is a direct PAX3-FOXO1A target involved in alveolar rhabdomyosarcoma aggressiveness

被引:26
|
作者
Thuault, S. [1 ,2 ]
Hayashi, S. [3 ]
Lagirand-Cantaloube, J. [1 ,2 ]
Plutoni, C. [1 ,2 ]
Comunale, F. [1 ,2 ]
Delattre, O. [4 ]
Relaix, F. [3 ]
Gauthier-Rouviere, C. [1 ,2 ]
机构
[1] Univ Montpellier 2, CRBM, CNRS, UMR 5237, F-34293 Montpellier, France
[2] Univ Montpellier I, CRBM, CNRS, UMR 5237, F-34293 Montpellier, France
[3] INSERM UPMC AIM, UMRS787, Paris, France
[4] Inst Curie, INSERM Unite 830, Unite Genet Somat, Paris, France
关键词
P-cadherin; rhabdomyosarcoma; PAX3-FOXO1A; invasion; cadherin switch; TRANSCRIPTIONAL ACTIVATOR; SKELETAL MYOGENESIS; CELL-MIGRATION; GENE FUSIONS; PAX GENES; EXPRESSION; PAX3-FKHR; IDENTIFICATION; FAMILY; TRANSFORMATION;
D O I
10.1038/onc.2012.217
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Alveolar rhabdomyosarcoma (ARMS) is an aggressive childhood cancer of striated muscle characterized by the presence of the PAX3-FOXO1A or PAX7-FOXO1A chimeric oncogenic transcription factor. Identification of their targets is essential for understanding ARMS pathogenesis. To this aim, we analyzed transcriptomic data from rhabdomyosarcoma samples and found that P-cadherin expression is correlated with PAX3/7-FOXO1A presence. We then show that expression of a PAX3 dominant negative variant inhibits P-cadherin expression in ARMS cells. Using mouse models carrying modified Pax3 alleles, we demonstrate that P-cadherin is expressed in the dermomyotome and lies genetically downstream from the myogenic factor Pax3. Moreover, in vitro gel shift analysis and chromatin immunoprecipitation indicate that the P-cadherin gene is a direct transcriptional target for PAX3/7-FOXO1A. Finally, P-cadherin expression in normal myoblasts inhibits myogenesis and induces myoblast transformation, migration and invasion. Conversely, P-cadherin downregulation by small hairpin RNA decreases the transformation, migration and invasive potential of ARMS cells. P-cadherin also favors cadherin switching, which is a hallmark of metastatic progression, by controlling N- and M-cadherin expression and/or localization. Our findings demonstrate that P-cadherin is a direct PAX3-FOXO1A transcriptional target involved in ARMS aggressiveness. Therefore, P-cadherin emerges as a new and attractive target for therapeutic intervention in ARMS. Oncogene (2013) 32, 1876-1887; doi:10.1038/onc.2012.217; published online 18 June 2012
引用
收藏
页码:1876 / 1887
页数:12
相关论文
共 50 条
  • [31] PAX3-FOXO1 is essential for tumour initiation and maintenance but not recurrence in a human myoblast model of rhabdomyosarcoma
    Pandey, Puspa R.
    Chatterjee, Bishwanath
    Olanich, Mary E.
    Khan, Javed
    Miettinen, Markku M.
    Hewitt, Stephen M.
    Barr, Frederic G.
    JOURNAL OF PATHOLOGY, 2017, 241 (05): : 626 - 637
  • [32] Immunohistochemical detection of PAX-FOXO1 fusion proteins in alveolar rhabdomyosarcoma using breakpoint specific monoclonal antibodies
    Azorsa, David O.
    Bode, Peter K.
    Wachtel, Marco
    Cheuk, Adam Tai Chi
    Meltzer, Paul S.
    Vokuhl, Christian
    Camenisch, Ulrike
    Khov, Huy Leng
    Bode, Beata
    Schaefer, Beat W.
    Khan, Javed
    MODERN PATHOLOGY, 2021, 34 (04) : 748 - 757
  • [33] Synthetic MIR143-3p Suppresses Cell Growth in Rhabdomyosarcoma Cells by Interrupting RAS Pathways Including PAX3-FOXO1
    Sugito, Nobuhiko
    Heishima, Kazuki
    Ito, Yuko
    Akao, Yukihiro
    CANCERS, 2020, 12 (11) : 1 - 17
  • [34] Carnitine palmitoyltransferase 1A (CPT1A): a transcriptional target of PAX3-FKHR and mediates PAX3-FKHR-dependent motility in alveolar rhabdomyosarcoma cells
    Liu, Lingling
    Wang, Yong-Dong
    Wu, Jing
    Cui, Jimmy
    Chen, Taosheng
    BMC CANCER, 2012, 12
  • [35] Interleukin-24 (IL24) Is Suppressed by PAX3-FOXO1 and Is a Novel Therapy for Rhabdomyosarcoma
    Lacey, Alexandra
    Hedrick, Erik
    Cheng, Yating
    Mohankumar, Kumaravel
    Warren, Melanie
    Safe, Stephen
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (12) : 2756 - 2766
  • [36] The PAX3-FOXO1 Fusion Protein Present in Rhabdomyosarcoma Interferes with Normal FOXO Activity and the TGF-β Pathway
    Schmitt-Ney, Michel
    Camussi, Giovanni
    PLOS ONE, 2015, 10 (03):
  • [37] Therapeutic Approaches Targeting PAX3-FOXO1 and Its Regulatory and Transcriptional Pathways in Rhabdomyosarcoma
    Thanh Hung Nguyen
    Barr, Frederic G.
    MOLECULES, 2018, 23 (11):
  • [38] Myo-differentiation reporter screen reveals NF-Y as an activator of PAX3-FOXO1 in rhabdomyosarcoma
    Sroka, Martyna W.
    Skopelitis, Damianos
    Vermunt, Marit W.
    Preall, Jonathan B.
    El Demerdash, Osama
    de Almeida, Larissa M. N.
    Chang, Kenneth
    Utama, Raditya
    Gryder, Berkley
    Caligiuri, Giuseppina
    Ren, Diqiu
    Nalbant, Benan
    Milazzo, Joseph P.
    Tuveson, David A.
    Dobin, Alexander
    Hiebert, Scott W.
    Stengel, Kristy R.
    Mantovani, Roberto
    Khan, Javed
    Kohli, Rahul M.
    Shi, Junwei
    Blobel, Gerd A.
    Vakoc, Christopher R.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2023, 120 (36)
  • [39] Nephroblastoma overexpressed (NOV/CCN3) gene: a paired-domain-specific PAX3-FKHR transcription target that promotes survival and motility in alveolar rhabdomyosarcoma cells
    Zhang, Y.
    Wang, C.
    ONCOGENE, 2011, 30 (32) : 3549 - 3562
  • [40] Negative correlation of single-cell PAX3:FOXO1 expression with tumorigenicity in rhabdomyosarcoma
    Regina, Carla
    Hamed, Ebrahem
    Andrieux, Geoffroy
    Angenendt, Sina
    Schneider, Michaela
    Ku, Manching
    Follo, Marie
    Wachtel, Marco
    Ke, Eugene
    Kikuchi, Ken
    Henssen, Anton G.
    Schafer, Beat W.
    Boerries, Melanie
    Wagers, Amy J.
    Keller, Charles
    Hettmer, Simone
    LIFE SCIENCE ALLIANCE, 2021, 4 (09)